forpressrelease Mail to a Friend
forpressrelease Rate forpressrelease forpressrelease forpressrelease forpressrelease forpressrelease 

Creative Biolabs Introduced Efalizumab for the Psoriasis Lab Research



2024-03-26 10:40:22 Technology

499


Sep 21th, 2018, as a world-leading supplier and manufacturer in antibody production for lab use, Creative Biolabs has introduced its newly-developed efalizumab for the research projects related to psoriasis, which is a long-lasting autoimmune disease characterized by patches of abnormal skin, known as Koebner phenomenon.

It is well known that efalizumab is a kind of method for progressive multifocal leukoencephalopathy (PML), which occurs in people whose immune systems have been severely weakened and often leads to an irreversible decline in neurologic function and death. However, this treatment had been withdrawn by FDA in USA due to its life-threatening infections. What?s more, some other known side effects are involving bacterial sepsis, invasive fungal diseases, etc.

However, recently, efalizumab is proved to be an effective approach for the treatment of chronic moderate to severe plaque psoriasis which is generally thought to be a genetic disease that is triggered by environmental factors.

?People are more familiar with that raptiva efalizumab is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. The essence is that it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.? Explained by Dr. Monika, scientific officer of Creative Biolabs, ?and it binds to the CD11a subunit of lymphocyte function-associated antigen 1, acting as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues.?

?in Creative Biolabs, of course, we provide it only for lab use, not for diagnostic, therapeutic or any other in vivo human use. Its function is tested and guaranteed by our scientists who are well-experienced and professional. Clients can use our product for clinical use for adults with chronic moderate to severe plaque psoriasis.? Dr. Lin added. ?we develop efalizumab with the molecular weight of 150 kilodaltons from hamster ovary mammalian cell expression system in a nutrient medium with the antibiotic gentamicin. So we can guarantee its high quality and high specificity.?

Indeed, it is reported that there is no cure for psorasis. Therefore it is eager to make changes in this field. Creative Biolabs indicated that it will be support researchers with high-qaultiy lab use products and services in order to make it successful sooner, hoping it can make more for the benefit of our human beings.

About Creative Biolabs
Over the past ten years, Creative Biolabs has served more than 100 million researchers from all over the world. And with the high-quality products and professional services, it has gained great fame among the antibody production field.

User :- Bella Smith

Email :-biolabs-marketing@outlook.com

Phone :---

Mobile:- -






Related Post

Advertisement